Recipharm Pharmaceutical Development and Synthonics have entered a dual-promotion agreement through which the former firm’s customers will have full access to the latter company’s metal coordination chemistry, which has been shown to improve drug delivery and absorption. Financial terms of the agreement were not disclosed.
In a statement, Recipharm general manager Maria Lundberg noted: “The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products.”
Synthonics’ Ken Slepicka, CEO, added that his firm believes its chemistry will integrate well with Recipharm’s existing solutions.